Literature DB >> 26768137

A multidimensional antimicrobial stewardship intervention targeting aztreonam use in patients with a reported penicillin allergy.

Sara M Swearingen1, Cyle White2, Sara Weidert3, Melisande Hinds4, John P Narro5, Anthony J Guarascio6.   

Abstract

BACKGROUND: Local antimicrobial susceptibility patterns should be considered for antimicrobial therapy decisions. Antibiogram data can guide beta-lactam antibiotic use in the presence of a penicillin allergy, particularly when allergic cross-reactivity among antibiotic agents is unlikely.
OBJECTIVE: To evaluate the effect of a multidimensional antimicrobial stewardship intervention to improve antibiogram-driven antibiotic selection for patients with a reported penicillin allergy receiving aztreonam.
METHODS: This historically controlled, quasi-experimental study compared historical aztreonam use with prospective antibiotic selection following a pharmacist-led intervention in patients with a penicillin allergy. The impact of this intervention on aztreonam use, antimicrobial selection, patient allergy profile updates, length of stay, in-hospital mortality, and antibiotic cost savings was assessed.
RESULTS: A significant reduction in median days of aztreonam therapy (4.0 vs. 2.0; p = 0.0001) and median days of therapy per 1000 patient days (14.5 vs. 9.3; p = 0.0001) was found in the intervention group.
CONCLUSION: A pharmacist-led antimicrobial stewardship intervention facilitated antibiogram-driven antibiotic therapy while reducing aztreonam use in patients without an anaphylactic penicillin allergy. Further trials are needed to assess the utility of similar antimicrobial stewardship interventions for patients with penicillin allergy.

Entities:  

Keywords:  Antibiogram; Antibiotic resistance; Antimicrobial stewardship; Beta-lactam antibiotics; Drug allergy; Infectious diseases; Medical education

Mesh:

Substances:

Year:  2016        PMID: 26768137     DOI: 10.1007/s11096-016-0248-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

1.  A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance.

Authors:  Carlos Bantar; Beatriz Sartori; Eduardo Vesco; Claudia Heft; Mariano Saúl; Francisco Salamone; María Eugenia Oliva
Journal:  Clin Infect Dis       Date:  2003-07-09       Impact factor: 9.079

2.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

3.  Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy.

Authors:  Ronald E Polk; Christina Fox; Anne Mahoney; Jim Letcavage; Conan MacDougall
Journal:  Clin Infect Dis       Date:  2007-01-22       Impact factor: 9.079

Review 4.  The use of cephalosporins in penicillin-allergic patients: a literature review.

Authors:  James D Campagna; Michael C Bond; Esteban Schabelman; Bryan D Hayes
Journal:  J Emerg Med       Date:  2011-07-13       Impact factor: 1.484

5.  Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy.

Authors:  E J MacLaughlin; J J Saseen; D C Malone
Journal:  Arch Fam Med       Date:  2000-08

6.  Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis.

Authors:  Michael E Pichichero; Janet R Casey
Journal:  Otolaryngol Head Neck Surg       Date:  2007-03       Impact factor: 3.497

7.  Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.

Authors:  Christina A Sutherland; David P Nicolau
Journal:  Clin Ther       Date:  2015-06-15       Impact factor: 3.393

8.  Antibiotic allergies in the medical record: effect on drug selection and assessment of validity.

Authors:  Dave M Lutomski; Jennifer A Lafollette; Michael A Biaglow; Lisa A Haglund
Journal:  Pharmacotherapy       Date:  2008-11       Impact factor: 4.705

9.  Likelihood of inadequate treatment: a novel approach to evaluating drug-resistance patterns.

Authors:  Heinz Burgmann; Brigitte Stoiser; Gottfried Heinz; Peter Schenk; Petra Apfalter; Konstantin Zedtwitz-Liebenstein; Michael Frass; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2009-07       Impact factor: 3.254

Review 10.  Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances?

Authors:  Jane Frumin; Jason C Gallagher
Journal:  Ann Pharmacother       Date:  2009-02-03       Impact factor: 3.154

  10 in total
  11 in total

Review 1.  Controversies in Drug Allergy: Drug Allergy Pathways.

Authors:  Anca M Chiriac; Aleena Banerji; Rebecca S Gruchalla; Bernard Y H Thong; Paige Wickner; Paul-Michel Mertes; Ingrid Terreehorst; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-17

Review 2.  The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration.

Authors:  Jason A Trubiano; Cosby A Stone; M Lindsay Grayson; Karen Urbancic; Monica A Slavin; Karin A Thursky; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017-08-23

Review 3.  Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation.

Authors:  Kimberly G Blumenthal; Erica S Shenoy; Anna R Wolfson; David N Berkowitz; Victoria A Carballo; Diana S Balekian; Kathleen A Marquis; Ramy Elshaboury; Ronak G Gandhi; Praveen Meka; David W Kubiak; Jennifer Catella; Barbara B Lambl; Joyce T Hsu; Monique M Freeley; Alana Gruszecki; Paige G Wickner
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

4.  Impact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation.

Authors:  Jason A Trubiano; Karin A Thursky; Andrew J Stewardson; Karen Urbancic; Leon J Worth; Cheryl Jackson; Wendy Stevenson; Michael Sutherland; Monica A Slavin; M Lindsay Grayson; Elizabeth J Phillips
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

Review 5.  Acute care beta-lactam allergy pathways: approaches and outcomes.

Authors:  Anna R Wolfson; Emily M Huebner; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2019-04-19       Impact factor: 6.347

Review 6.  Drug Allergy Delabeling Programs: Recent Strategies and Targeted Populations.

Authors:  Karen M Anstey; Lulu Tsao; Iris M Otani
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-15       Impact factor: 8.667

7.  Prevalence and characteristics of hospital inpatients with reported fluoroquinolone allergy.

Authors:  Geoffrey C Wall; Matthew J Taylor; Hayden L Smith
Journal:  Int J Clin Pharm       Date:  2018-03-14

8.  Improving Antimicrobial Stewardship by Antibiotic Allergy Delabeling: Evaluation of Knowledge, Attitude, and Practices Throughout the Emerging Infections Network.

Authors:  Jason A Trubiano; Susan E Beekmann; Leon J Worth; Philip M Polgreen; Karin A Thursky; Monica A Slavin; M Lindsay Grayson; Elizabeth J Phillips
Journal:  Open Forum Infect Dis       Date:  2016-09-03       Impact factor: 3.835

9.  Improving Aztreonam Stewardship and Cost Through a Penicillin Allergy Testing Clinical Guideline.

Authors:  Justin R Chen; Scott A Tarver; Kristin S Alvarez; Wenjing Wei; David A Khan
Journal:  Open Forum Infect Dis       Date:  2018-05-05       Impact factor: 3.835

10.  Outcomes from an inpatient beta-lactam allergy guideline across a large US health system.

Authors:  Kimberly G Blumenthal; Yu Li; Joyce T Hsu; Anna R Wolfson; David N Berkowitz; Victoria A Carballo; Jesse M Schwartz; Kathleen A Marquis; Ramy Elshaboury; Ronak G Gandhi; Barbara B Lambl; Monique M Freeley; Alana Gruszecki; Paige G Wickner; Erica S Shenoy
Journal:  Infect Control Hosp Epidemiol       Date:  2019-03-27       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.